Use of cellular immunotherapy for treatment of refractory acute myeloid leukemia by Loren Fast et al.
POSTER PRESENTATION Open Access
Use of cellular immunotherapy for treatment
of refractory acute myeloid leukemia
Loren Fast*, John Reagan, Peter Quesenberry
From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013
A previous clinical trial carried out by our group in which
high numbers of haploidentical donor lymphoid cells con-
taining CD3+ cells (1 - 2 x 108 CD3+ cells/kg) were infused
into recipients with refractory hematological malignancy
found that 14/27 patients gave a response, 9 or which were
major. These recipients rapidly developed a cytokine storm
which was resolved, if needed, by administrating steroids.
No persisting donor cells could be detected at 2 weeks fol-
lowing infusion. After gaining FDA and IRB approval, this
cellular immunotherapy trial was restarted. One of the
goals of the trial was to define the effector mechanisms
that were playing a role in anti-leukemic responses. The
results from the first recipient enrolled indicated that right
after the infusion, 11.3% of peripheral blood mononuclear
cells were donor cells as defined by donor-specific anti-
HLA antibodies. Donor cell levels had decreased to 0.95%
on day 7. Increased expression of granzymes and perforin
by both donor and recipient cells especially 2 - 3 days after
infusion indicated that these cells exhibited increased cyto-
lytic activity. In addition, both donor and recipient CD4+
cells were found to express increased levels of CD134, and
a large fraction of CD8+ cells expressed CD279 (PD-1).
The role of cytolytic cells will be assessed further as addi-
tional patients are enrolled and the expression of activating
or inhibitory receptors will be confirmed. These results
could suggest additional therapeutic approaches to be
tested for enhancing the anti-leukemic responses following
cellular immunotherapy.
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